Dynavax (DVAX) Receives a Buy from William Blair

By Ryan Adsit

William Blair analyst Matt Phipps maintained a Buy rating on Dynavax (DVAXResearch Report) on August 13. The company’s shares closed last Monday at $3.91, close to its 52-week low of $2.60.

According to TipRanks.com, Phipps has currently no stars on a ranking scale of 0-5 stars, with an average return of -21.9% and a 30.0% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics Plc, Kezar Life Sciences Inc, and Pieris Pharmaceuticals.

Currently, the analyst consensus on Dynavax is a Strong Buy with an average price target of $16, representing a 329.0% upside. In a report issued on August 8, Cowen & Co. also maintained a Buy rating on the stock with a $20 price target.

See today’s analyst top recommended stocks >>

Based on Dynavax’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $42.71 million. In comparison, last year the company had a GAAP net loss of $39.44 million.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DVAX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.